Edition:
United Kingdom

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

86.03USD
16 Feb 2018
Change (% chg)

$0.44 (+0.51%)
Prev Close
$85.59
Open
$85.55
Day's High
$88.19
Day's Low
$84.51
Volume
812,810
Avg. Vol
579,461
52-wk High
$153.14
52-wk Low
$80.99

Chart for

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $24,161.52
Shares Outstanding(Mil.): 210.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Incyte Corp Q4 Loss Per Share $0.71

* INCYTE REPORTS 2017 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS

15 Feb 2018

BRIEF-Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

* INCYTE UPDATES CONFERENCE CALL TIME TO REPORT FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Source text for Eikon: Further company coverage:

31 Jan 2018

BRIEF-Syros Pharmaceuticals Enters Amendment To Stock Purchase Agreement With Incyte

* SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING​

31 Jan 2018

BRIEF-Incyte Corp Recommends Shareholders Reject Mini-Tender Offer By TRC Capital

* INCYTE CORPORATION RECOMMENDS SHAREHOLDERS REJECT MINI-TENDER OFFER BY TRC CAPITAL CORPORATION

23 Jan 2018

BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement

* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT

08 Jan 2018

BRIEF-Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia

* Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia

15 Nov 2017

BRIEF-Incyte says Q3 earnings per share $0.17

* Incyte reports 2017 third-quarter financial results and updates on key clinical programs

31 Oct 2017

AstraZeneca plans new pivotal lung cancer trial with Incyte

LONDON AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.

31 Oct 2017

AstraZeneca plans new pivotal lung cancer trial with Incyte

LONDON AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.

31 Oct 2017

AstraZeneca plans new pivotal lung cancer trial with Incyte

LONDON, Oct 31 AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.

31 Oct 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.26 +0.55
Abbott Laboratories (ABT.N) $60.17 +0.67
Amgen, Inc. (AMGN.OQ) $183.55 -0.05
Biogen Inc (BIIB.OQ) $291.87 -7.51
Roche Holding Ltd. (ROG.S) CHF223.05 -2.45
Roche Holding Ltd. (RO.S) CHF226.60 -3.60
Sanofi SA (SASY.PA) €64.19 -0.31

Earnings vs. Estimates